Biomaterials for inflammatory bowel disease: treatment, diagnosis and organoids
Source abstract
Abstract
Inflammatory bowel disease (IBD) is a chronic gastrointestinal disease characterized by intestinal tract inflammation. Although the incidence of IBD is increasing globally, the mechanisms underlying its pathogenesis remain unclear. Numerous drugs have been recently used to treat the disease; however, they have several shortcomings, such as poor stability, poor solubility, and low biosafety. In recent years, research on biomaterials to address the challenges encountered in IBD treatment has increased and is extensive. Different types of biomaterials play different roles in IBD due to their unique characteristics, and different types of macromolecular preparations are applied according to their physical and chemical properties. In addition, biomaterial-based drug delivery systems are expected to overcome the limitations of traditional oral drug delivery, and offer novel opportunities for IBD treatment via oral drug administration. Intestinal organoids have also become a research hotspot in recent years in IBD studies, with key roles in IBD pathogenesis, drug screening. The present article reviews research and the roles of various biomaterials in IBD treatment to enhance our understanding of research trends in biomaterials in IBD in recent years and facilitate IBD treatment and further research.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Inhalation and Respiratory Drug Delivery · Inflammatory Bowel Disease · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. A comprehensive review and update on the pathogenesis of inflammatory bowel disease10.1155/2019/7247238 ↗
2. The epidemiology of inflammatory bowel disease: east meets west10.1111/jgh.14872 ↗
3. Inflammatory bowel diseases and gut microbiota10.3390/ijms24043817 ↗
4. Secondary causes of inflammatory bowel diseases10.3748/wjg.v26.i28.3998 ↗
5. Perspectives on current and novel treatments for inflammatory bowel disease10.5009/gnl19019 ↗
6. New insights of oral colonic drug delivery systems for inflammatory bowel disease therapy10.3390/ijms21186502 ↗
7. Nanotechnology impacting probiotics and prebiotics: a paradigm shift in nutraceuticals technology10.1016/j.ijfoodmicro.2022.110083 ↗
8. Marine biomaterials in biomedical nano/micro-systems10.1186/s12951-023-02112-w ↗
9. Cysteine-based biomaterials as drug nanocarriers10.1002/adtp.201900142 ↗
10. Modifications of polysaccharide-based biomaterials under structure-property relationship for biomedical applications10.1016/j.carbpol.2021.118097 ↗
11. Application of metal-based biomaterials in wound repair
12. Recent advances of poly(ester amide)s-based biomaterials10.1021/acs.biomac.2c00150 ↗
13. Gut microbiome structure and metabolic activity in inflammatory bowel disease10.1038/s41564-018-0306-4 ↗
14. Toll-like receptors and inflammatory bowel disease10.3389/fimmu.2018.00072 ↗
15. Intestinal organoids for modelling intestinal development and disease10.1098/rstb.2017.0217 ↗
16. Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome10.1016/j.addr.2021.114021 ↗
17. Plant-derived exosomes as a drug-delivery approach for the treatment of inflammatory bowel disease and colitis-associated cancer10.3390/pharmaceutics14040822 ↗
18. Nanozyme-mediated catalytic nanotherapy for inflammatory bowel disease10.7150/thno.33727 ↗
19. A drug-free nanozyme for mitigating oxidative stress and inflammatory bowel disease10.1186/s12951-022-01319-7 ↗
20. Gastrointestinal physiology and function10.1007/164_2016_118 ↗
21. Oral delivery of proteins and peptides: challenges, status quo and future perspectives10.1016/j.apsb.2021.04.001 ↗
22. Understanding the biology of human interstitial cells of cajal in gastrointestinal motility10.3390/ijms21124540 ↗
23. Genetics and pathogenesis of inflammatory bowel disease10.1038/nature10209 ↗
24. Biomaterial-based gene therapy
25. Genetics and pathogenesis of inflammatory bowel disease10.1146/annurev-pathol-012615-044152 ↗
26. genetics of inflammatory bowel diseases10.1053/j.gastro.2015.08.001 ↗
27. Pharmacologic management of monogenic and very early onset inflammatory bowel diseases10.3390/pharmaceutics15030969 ↗
28. Interleukin-4 gene polymorphisms in romanian patients with inflammatory bowel diseases: association with disease risk and clinical features10.3390/diagnostics13081465 ↗
29. Immunoepigenetic regulation of inflammatory bowel disease: current insights into novel epigenetic modulations of the systemic immune response10.3390/genes14030554 ↗
30. Immunopathology of inflammatory bowel disease10.3748/wjg.v20.i1.6 ↗
31. The role of intestinal immune cells and matrix metalloproteinases in inflammatory bowel disease
32. Identification of gene signatures associated with ulcerative colitis and the association with immune infiltrates in colon cancer
33. Role of CD34 in inflammatory bowel disease
34. Therapeutic implications of diet in inflammatory bowel disease and related immune-mediated inflammatory diseases10.3390/nu13030890 ↗
35. Genetic and environmental considerations for inflammatory bowel disease10.1016/j.suc.2019.08.014 ↗
36. Gut microbiota in the pathogenesis of inflammatory bowel disease10.1007/s12328-017-0813-5 ↗
37. The interplay between microbes and the immune response in inflammatory bowel disease10.1113/JP275396 ↗
38. Impact of genes and the environment on the pathogenesis and disease course of inflammatory bowel disease10.1007/s10620-019-05648-w ↗
39. Molecular mechanisms of chitosan interactions with fungi and plants10.3390/ijms20020332 ↗
40. Hydrophilic chitosan derivatives: synthesis and applications
41. Antimicrobial chitosan conjugates: current synthetic strategies and potential applications10.3390/ijms21020499 ↗
42. Application of biomedical microspheres in wound healing10.3390/ijms24087319 ↗
43. Zinc improves antibacterial, anti-inflammatory and cell motility activity of chitosan for wound healing applications10.1016/j.ijbiomac.2022.05.199 ↗
44. Chitosan Ameliorates DSS-Induced Ulcerative Colitis Mice by Enhancing Intestinal Barrier Function and Improving Microflora10.3390/ijms20225751 ↗
45. Chitosan derivatives and their application in biomedicine10.3390/ijms21020487 ↗
46. Advances in the colon-targeted chitosan based multiunit drug delivery systems for the treatment of inflammatory bowel disease10.1016/j.carbpol.2022.119351 ↗
47. Chitosan/polyethylene glycol blend fibers and their properties for drug controlled release10.1002/jbm.a.31544 ↗
48. Structures and properties of chitosan-starch-sodium benzoate blend films
49. All-in-one theranostic nano-platform based on polymer nanoparticles for BRET/FRET-initiated bioluminescence imaging and synergistically anti-inflammatory therapy for ulcerative colitis10.1186/s12951-022-01299-8 ↗
50. Hyaluronic acid: redefining its role10.3390/cells9071743 ↗
51. Synergistic regenerative therapy of thin endometrium by human placenta-derived mesenchymal stem cells encapsulated within hyaluronic acid hydrogels10.1186/s13287-022-02717-2 ↗
52. Structures, properties, and bioengineering applications of alginates and hyaluronic acid10.3390/polym15092149 ↗
53. Hyaluronic acid increases anti-inflammatory efficacy of rectal 5-amino salicylic acid administration in a murine colitis model10.4062/biomolther.2020.227 ↗
54. Hyaluronan: a neuroimmune modulator in the microbiota-gut axis10.3390/cells11010126 ↗
55. Modulation of gut barrier functions in ulcerative colitis by hyaluronic acid system
56. Angiogenic microspheres for the treatment of a thin endometrium10.1021/acsbiomaterials.1c00615 ↗
57. Cellulose: characteristics and applications for rechargeable batteries10.1016/j.ijbiomac.2022.08.026 ↗
58. Cellulose nanofibers improve the performance of retrograded starch/pectin microparticles for colon-specific delivery of 5-ASA10.3390/pharmaceutics13091515 ↗
59. Development of microparticles for oral administration of Periplaneta americana extract to treat ulcerative colitis10.1080/10717544.2022.2112115 ↗
60. Comparison of 5-ASA layered or matrix pellets coated with a combination of ethylcellulose and eudragits L and s in the treatment of ulcerative colitis in rats10.1016/j.ijpharm.2023.122981 ↗
61. Unfermented β-fructan Fibers fuel inflammation in select inflammatory bowel disease patients10.1053/j.gastro.2022.09.034 ↗
62. The complex biological effects of pectin: galectin-3 targeting as potential human health improvement?10.3390/biom12020289 ↗
63. Pectin and pectin-based composite materials: beyond food texture10.3390/molecules23040942 ↗
64. Enzymatically extracted apple pectin possesses antioxidant and antitumor activity10.3390/molecules26051434 ↗
65. The effects of different dietary fiber pectin structures on the gastrointestinal immune barrier: impact via gut microbiota and direct effects on immune cells10.1038/s12276-020-0449-2 ↗
66. The dietary fiber pectin: health benefits and potential for the treatment of allergies by modulation of gut microbiota10.1007/s11882-021-01020-z ↗
67. Pectin based hydrogels for drug delivery applications: a mini review10.3390/gels8120834 ↗
68. Gelatin as it is: history and modernity10.3390/ijms24043583 ↗
69. Synthesis and evaluation of alginate, gelatin, and hyaluronic acid hybrid hydrogels for tissue engineering applications10.1016/j.ijbiomac.2023.123438 ↗
70. Preparation and physicochemical characterization of gelatin-aldehyde derivatives10.3390/molecules27207003 ↗
71. Physicochemical and antioxidant properties of gelatin and gelatin hydrolysates obtained from extrusion-pretreated fish (Oreochromis sp.) scales10.3390/md19050275 ↗
72. Development of chitosan, gelatin and liposome film and analysis of its biocompatibility in vitro10.1016/j.ijbiomac.2020.05.229 ↗
73. Gelatin nanoparticles enable water dispersibility and potentialize the antimicrobial activity of Buriti (Mauritia flexuosa) oil10.1186/s12896-020-00649-4 ↗
74. Research progress of natural silk fibroin and the application for drug delivery in chemotherapies
75. Emerging 3D bioprinting applications in plastic surgery10.1186/s40824-022-00338-7 ↗
76. Antioxidation and anti-inflammatory effects of gamma-irradiated silk sericin and fibroin in H2O2-induced HaCaT Cell10.4196/kjpp.2023.27.1.105 ↗
77. Optimizing the preparation of silk fibroin nanoparticles and their loading with polyphenols: towards a more efficient anti-inflammatory effect on macrophages10.3390/pharmaceutics15010263 ↗
78. Accelerated simple preparation of curcumin-loaded silk fibroin/hyaluronic acid hydrogels for biomedical applications10.3390/polym15030504 ↗
79. Postharvest ripening of two varieties of corns: structure, antioxidant activities and physicochemical properties of zein10.1016/j.fochx.2023.100680 ↗
80. Zein-based nanoparticles: preparation, characterization, and pharmaceutical application
81. Zein nanoparticles containing arginine-phenylalanine-based surfactants: stability, antimicrobial and hemolytic activity10.3390/nano13010200 ↗
82. Curcumin encapsulated zein/caseinate-alginate nanoparticles: release and antioxidant activity under in vitro simulated gastrointestinal digestion10.1016/j.crfs.2023.100463 ↗
83. The link between polyphenol structure, antioxidant capacity and shelf-life stability in the presence of fructose and ascorbic acid10.3390/molecules25010225 ↗
84. Extraction and analysis of polyphenols: recent trends10.3109/07388551.2010.513677 ↗
85. Natural polyphenols: chemical classification, definition of classes, subcategories, and structures10.5740/jaoacint.19-0133 ↗
86. Antioxidant activity and polyphenol composition of sugarcane molasses extract10.1016/j.foodchem.2020.126180 ↗
87. The immunomodulatory and anti-inflammatory role of polyphenols10.3390/nu10111618 ↗
88. Antimicrobial polyphenol-rich extracts: applications and limitations in the food industry10.1016/j.foodres.2020.109214 ↗
89. Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis10.1186/s40168-021-01115-9 ↗
90. Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy10.7150/thno.47601 ↗
91. Structural basis of polyethylene glycol recognition by antibody10.1186/s12929-019-0589-7 ↗
92. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized10.1016/j.jaip.2018.12.003 ↗
93. Structure and intermolecular interactions in aqueous solutions of polyethylene glycol10.3390/molecules27082573 ↗
94. Luminal polyethylene glycol solution delays the onset of preservation injury in the human intestine10.1111/ajt.16418 ↗
95. Surface functionalization of PLGA nanoparticles for potential oral vaccine delivery targeting intestinal immune cells10.1016/j.colsurfb.2022.113121 ↗
96. An update on pharmaceutical strategies for oral delivery of therapeutic peptides and proteins in adults and pediatrics10.3390/children7120307 ↗
97. A PEGylated nanostructured lipid carrier for enhanced oral delivery of antibiotics10.3390/pharmaceutics14081668 ↗
98. Effectiveness of very low-volume preparation for colonoscopy: a prospective, multicenter observational study10.3748/wjg.v26.i16.1950 ↗
99. PLGA/PLA-based long-acting injectable depot microspheres in clinical use: production and characterization overview for protein/peptide delivery10.3390/ijms22168884 ↗
100. Functional biomaterials for osteoarthritis treatment: from research to application10.1002/SMMD.20220014 ↗